Cargando…

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib

BACKGROUND: Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribocicl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, Marzia, Crucitta, Stefania, Omarini, Claudia, Bargagna, Irene, Mongillo, Marta, Palleschi, Michela, Stucci, Stefania, Meattini, Icro, D'Onofrio, Raffaella, Lorenzini, Giulia, Biondani, Pamela, De Giorgi, Ugo, Porta, Camillo, Livi, Lorenzo, Natalizio, Salvatore, Fontana, Andrea, Giontella, Elena, Angelini, Lucia, Fogli, Stefano, Danesi, Romano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593796/ https://www.ncbi.nlm.nih.gov/pubmed/36283134 http://dx.doi.org/10.1016/j.breast.2022.10.005

Ejemplares similares

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial
por: Banini, Marco, et al.
Publicado: (2023)

Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
por: Del Re, Marzia, et al.
Publicado: (2021)

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
por: Del Re, Marzia, et al.
Publicado: (2020)

The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs
por: Del Re, Marzia, et al.
Publicado: (2022)

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
por: Del Re, Marzia, et al.
Publicado: (2019)

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
por: Arrigoni, Elena, et al.
Publicado: (2018)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Fully automated volumetric modulated arc therapy technique for radiation therapy of locally advanced breast cancer
por: Marrazzo, Livia, et al.
Publicado: (2023)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
por: Cucchiara, Federico, et al.
Publicado: (2020)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018)

The Italian Association for Radiotherapy and Clinical Oncology (AIRO) position statements for postoperative breast cancer radiation therapy volume, dose, and fractionation
por: Meattini, Icro, et al.
Publicado: (2022)

Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications
por: Internò, Valeria, et al.
Publicado: (2022)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice
por: Stucci, Luigia Stefania, et al.
Publicado: (2021)

Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NOD.CB17 mice
por: Felici, Claudia, et al.
Publicado: (2022)

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
por: Arrigoni, Elena, et al.
Publicado: (2017)

Subcutaneous Tissue Expander Placement with Synthetic Titanium-Coated Mesh in Breast Reconstruction: Long-term Results
por: Casella, Donato, et al.
Publicado: (2016)

Special issue. De-escalation of loco-regional treatment in breast cancer: Time to find the balance? Partial breast irradiation
por: Meattini, Icro, et al.
Publicado: (2023)

Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview
por: Internò, Valeria, et al.
Publicado: (2021)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Ribociclib in newly diagnosed hepatitis B infection: A case report
por: Di Costanzo, Fabrizio, et al.
Publicado: (2023)

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment
por: Al-Shdefat, Ramadan, et al.
Publicado: (2023)

Multiple Cutaneous Angiosarcomas after Breast Conserving Surgery and Bilateral Adjuvant Radiotherapy: An Unusual Case and Review of the Literature
por: Meattini, Icro, et al.
Publicado: (2014)

hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer
por: Iorio, Jessica, et al.
Publicado: (2018)

Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists
por: Meattini, Icro, et al.
Publicado: (2020)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bqr65r5l0eom1nd2mf04d71f99